Traws Pharma Inc

TRAW.US
Healthcare · Biotechnology
0.51
-0.01 (-1.35%)
USD · NASDAQ

Company Information

Company Name
Traws Pharma Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US68232V8845
CIK: 0001130598
CUSIP: 68232V884
Currency: USD
Full Time Employees: 4
Phone: 267 759 3680
Fiscal Year End: December
IPO Date: Jan 02, 2001
Description:

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Address:

12 Penns Trail, Newtown, PA, United States, 18940

People

Directors & Officers

Name Title Year Born
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. CEO, Secretary & Director 1958
Dr. Nikolay Savchuk Ph.D. COO & Director 1969
Dr. Charles David Pauza Ph.D. Chief Scientific Officer of Virology 1955
Mr. Charles Parker Chief Financial Officer 1981
Dr. Victor Mandia Moyo M.D. Chief Medical Officer of Oncology 1969
Dr. Robert R. Redfield M.D. Chief Medical Officer 1952

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Adage Capital Partners Gp LLC 730.00K Mar 31, 2026 4.79% $0.00 0.00%
Ikarian Capital, LLC 678.14K Mar 31, 2026 4.45% $0.10 0.00%
Orbimed Advisors, LLC 605.53K Mar 31, 2026 3.98% $0.02 0.00%
Squadron Capital Management LLC 511.71K Mar 31, 2026 3.36% $0.34 -28.29%
Dauntless Investment Group, LLC 417.00K Mar 31, 2026 2.74% $0.51 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 194.54K Mar 31, 2026 1.28% $0.00 0.00%
ADAR1 Capital Management LLC 154.10K Mar 31, 2026 1.01% $0.02 -0.22%
Vanguard Group Inc 87.26K Dec 31, 2025 0.57% $0.00 0.00%
Geode Capital Management, LLC 77.10K Mar 31, 2026 0.51% $0.00 25.06%
Palumbo Wealth Management LLC 61.18K Mar 31, 2026 0.40% $0.03 0.00%
Vanguard Capital Management, LLC 55.19K Mar 31, 2026 0.36% $0.00 0.00%
Vanguard Fiduciary Trust Co 31.80K Mar 31, 2026 0.21% $0.00 0.00%
State Street Corp 25.80K Mar 31, 2026 0.17% $0.00 0.00%
Jane Street Group LLC 21.24K Mar 31, 2026 0.14% $0.00 0.00%
Two Sigma Investments LLC 19.24K Mar 31, 2026 0.13% $0.00 0.00%
Lynx1 Capital Management, LP 15.08K Mar 31, 2026 0.10% $0.00 0.00%
BlackRock Inc 9.96K Mar 31, 2026 0.07% $0.00 0.00%
UBS Group AG 4.05K Mar 31, 2026 0.03% $0.00 -47.51%
Tower Research Capital LLC 3.96K Mar 31, 2026 0.03% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 3.73K Mar 31, 2026 0.02% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 177.20K 1.16% ▲ 0.00% Jun 30, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 152.85K 1.00% ▲ 176.94% Jun 30, 2026
3 Blackrock Extended Mkt Fund CF 50.34K 0.33% ▲ 0.00% May 31, 2026
4 Fidelity Extended Market Index 39.34K 0.26% ▼ 15.29% May 31, 2026
5 NT Ext Equity Mkt Index Fund - Lending 24.42K 0.16% ▲ 4,863.62% Jun 30, 2026
6 NT Ext Equity Mkt Index Fund - NL 12.97K 0.09% ▲ 1,826.89% Jun 30, 2026
7 Spartan Extended Market Index Pool F 10.07K 0.07% ▲ 0.00% May 31, 2026
8 NT Ext Equity Mkt Idx Fd - DC - NL - T2 9.41K 0.06% ▲ 1,681.82% Jun 30, 2026
9 Fidelity Series Total Market Index 8.10K 0.05% ▲ 0.00% May 31, 2026
10 Fidelity Total Market Index 7.47K 0.05% ▲ 0.00% May 31, 2026

Financial Highlights

Market Cap: $7.92M
EBITDA: $-19.51M
Book Value: $-0.52
Earnings/Share: $-1.87
Profit Margin: 0.00%
Operating Margin: -717.82%
ROA (TTM): -90.09%
ROE (TTM): -5,639.19%
Revenue (TTM): $2.73M
Revenue/Share (TTM): $0.30
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $4.46M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 15.23M
Shares Float: 11.73M
% Insiders: 538.20%
% Institutions: 4,393.40%
Short % Float: 5.42%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$2.79M
Cost of Goods Sold
adjust
$-61.00K
Gross Profit
subtotal
$2.79M
SG&A
adjust
$-8.52M
R&D
adjust
$-12.14M
Operating Income
subtotal
$-17.88M
Other / Non-Operating Items
adjust
$27.05M
Net Income
subtotal
$9.17M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TRAW.US!